Lv1
18 积分 2025-04-09 加入
[China lymphoma diagnosis and treatment guideline (2026 edition)]
24天前
已完结
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer
1个月前
已完结
Hallmarks of aging: An expanding universe
1个月前
已完结
From geroscience to precision geromedicine: Understanding and managing aging
1个月前
已完结
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
2个月前
已完结
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
2个月前
已完结
Artificial intelligence in drug development
3个月前
已完结
Guidelines for the diagnosis and treatment of refractory chronic spontaneous urticaria in China （2025 edition）
4个月前
已完结
Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study
4个月前
已完结
皖公网安备34019202002308
